Studies first-line immunotherapy in metastatic melanoma patients in Slovenia
Tests immunotherapy as first treatment in adults with spreading melanoma skin cancer.
Plain-language title generated from the registry record
Registry title: Efficacy of First-Line Immunotherapy in Metastatic Melanoma in Slovenia and Identification of Predictive Biomarkers
Key facts
- Where
- Ljubljana, SloveniaSee the site
Where in Slovenia
- Institute of Oncology LjubljanaLjubljana, SloveniaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Institute of Oncology Ljubljana
- Trial code
- NCT07407166
- Record updated
- 17 February 2026
- Original description
This study evaluates the effectiveness of first-line immunotherapy in patients with metastatic melanoma treated at the Institute of Oncology Ljubljana in Slovenia. The main objectives are to assess treatment response rates, progression-free survival, and treatment safety, and to identify prognostic and predictive biomarkers associated with response to immunotherapy.Read full original descriptionShow less
Efficacy of Immunotherapy in the First Line of Treatment of Diffuse Melanoma in Slovenia and Recognition of Prognostic and Predictive Biomarkers From Primary Tumor, Faeces and Body Fluids
This study evaluates the effectiveness of first-line immunotherapy in patients with metastatic melanoma treated at the Institute of Oncology Ljubljana in Slovenia. The main objectives are to assess treatment response rates, progression-free survival, and treatment safety, and to identify prognostic and predictive biomarkers associated with response to immunotherapy.
Biological samples including blood, stool, and body fluids (if available) will be collected at predefined time points and analyzed for molecular tumor markers. Imaging assessments (CT or PET/CT) will be performed before treatment initiation and during follow-up to evaluate response.
The study aims to improve identification of patient subgroups who benefit from immunotherapy and those who do not, supporting better personalized treatment strategies.
Inclusion: Age ≥ 18 years; Metastatic (diffuse) melanoma; Planned first-line immunotherapy treatment; Signed informed consent for participation in the study.
Exclusion: Any condition preventing participation or sample collection according to investigator judgment; Age < 18 years; Inability to provide informed consent.